Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Zelira Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $10.67 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 11.35 million
Earnings per share -0.554
Dividend per share N/A
Year To Date Return 3.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Zelira Therapeutics Ltd (ASX: ZLD)
    Latest News

    Lab worker puts hands in the air and dances around
    Healthcare Shares

    Guess which obscure ASX healthcare share just exploded 220% on HUGE news

    This ASX share has just tripled its investors' money.

    Read more »

    The sunset silhouette of a person leaping in the air as a large bird flies over head.
    Cannabis Shares

    Off and racing: Zelira shares fly 37% higher on Thursday

    The stock has gained a whopping 111% so far this week.

    Read more »

    An older man throws his hands up in excitement as he rides a carnival swing high up in the air.
    Share Gainers

    Why has this ASX medicinal cannabis share soared 49% in two days?

    German federal regulatory approval seems to have pleased investors.

    Read more »

    a medical person in white coat, gloves and protective eyewear uses tools and a test tube to put cannabis buds into the tube for research purposes.
    Share Market News

    Zelira shares rocket 28% before being placed on ice. Here's the latest.

    Zelira shareholders will have to wait until Thursday to find out the company's latest results from the German regulator.

    Read more »

    little green pharma share price represented by cannabis leaf character jumping cheerfully
    Cannabis Shares

    Blazing it? How the top ASX cannabis shares performed in FY21

    How did ASX cannabis shares fare in FY21?

    Read more »

    ASX Cannabis share price represented by asx investor holding card with cannabis leaf on it
    Cannabis Shares

    Why the Zelira (ASX:ZLD) share price is storming 7% higher

    The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its…

    Read more »

    A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares
    Cannabis Shares

    Zelira (ASX:ZLD) share price falls despite strong trading update

    The Zelira Therapeutics Ltd (ASX: ZLD) share price is sliding despite announcing a positive trading update. Here's what the company…

    Read more »

    Share Market News

    What will Elite Cannabinoids mean for ASX cannabis shares?

    Private cannabis company Elite Cannabinoids has received approval for cultivation in Western Australia. What about ASX cannabis shares?

    Read more »

    various forms of medicinal cannabis
    Cannabis Shares

    CBD to be sold in pharmacies, ASX cannabis shares react

    Last week, it became legal to sell cannabidiol (CBD) products in chemists and pharmacies. We take a look at the…

    Read more »

    cannabis leaves on a rising line graph representing growth of ASX cannabis share price
    Share Market News

    The sector that'll grow 480% this year, expert says

    Can you smell that? That's the fragrance of a booming industry, which is still in a startup phase in Australia.

    Read more »

    Best Shares

    5 top ASX cannabis shares in 2020

    We take a closer look at the 5 top ASX cannabis shares in 2020 and how they delivered for shareholders…

    Read more »

    man walking up line graph, into clouds, representing asx shares at an all time high
    Share Market News

    Here's why the Zelira (ASX:ZLD) share price just rocketed to a new high

    The Zelira Therapeutics Ltd (ASX: ZLD) share price is rocketing higher today after announcing a new licencing agreement with Alternative…

    Read more »

    ZLD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Zelira Therapeutics Ltd

    Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

    ZLD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Dec 2023 $0.94 $-0.09 -8.74% 4,331 $0.99 $1.02 $0.94
    29 Nov 2023 $1.03 $0.01 0.98% 2,634 $1.02 $1.03 $0.94
    28 Nov 2023 $1.02 $-0.04 -3.76% 2,265 $1.04 $1.10 $1.02
    27 Nov 2023 $1.07 $0.04 3.92% 4,956 $1.02 $1.07 $1.02
    24 Nov 2023 $1.02 $0.00 0.00% 3,282 $1.07 $1.07 $1.02
    23 Nov 2023 $1.02 $-0.03 -2.86% 4,097 $1.05 $1.07 $1.02
    22 Nov 2023 $1.05 $0.00 0.00% 2,936 $1.07 $1.07 $1.05
    21 Nov 2023 $1.05 $0.07 7.14% 3,334 $1.05 $1.05 $0.98
    20 Nov 2023 $0.98 $0.00 0.00% 4,436 $1.01 $1.01 $0.98
    17 Nov 2023 $0.98 $0.07 7.65% 3,576 $0.92 $1.07 $0.92
    16 Nov 2023 $0.92 $0.00 0.00% 2,253 $0.93 $0.95 $0.92
    15 Nov 2023 $0.92 $-0.04 -4.17% 10,097 $0.96 $0.96 $0.92
    14 Nov 2023 $0.96 $-0.09 -8.57% 2,628 $1.00 $1.00 $0.95
    13 Nov 2023 $1.05 $0.00 0.00% 2,001 $1.06 $1.06 $1.05
    10 Nov 2023 $1.05 $0.09 9.38% 4,342 $0.95 $1.06 $0.95
    09 Nov 2023 $0.96 $-0.02 -2.05% 6,867 $0.98 $0.98 $0.96
    08 Nov 2023 $0.98 $-0.01 -1.02% 1,952 $1.03 $1.03 $0.98
    07 Nov 2023 $0.99 $0.01 1.02% 10,729 $0.99 $1.10 $0.99
    03 Nov 2023 $0.98 $0.03 3.16% 3,944 $0.95 $0.99 $0.95
    02 Nov 2023 $0.95 $0.04 4.40% 1,133 $0.91 $0.95 $0.91

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Nov 2023 Timothy (Tim) Slate Issued 100,000 $47,335
    Director remuneration.
    24 Nov 2023 Oludare Odumosu Issued 200,000 $94,669
    Director remuneration. As per announcement on 24-11-2023
    24 Nov 2023 Osagie Imasogie Issued 150,000 $71,002
    Director remuneration.
    24 Nov 2023 Greg Blake Issued 175,000 $82,836
    Director remuneration.
    24 Nov 2023 Donna O'Donnell Issued 145,000 $91,430
    Director remuneration.
    11 Sep 2023 Greg Blake Expiry 114,290 $113,147
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Timothy (Tim) Ryan Slate Company SecretaryNon-Executive Director Dec 2016
    Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
    Dr Oludare Odumosu Managing Director Dec 2019
    Dr Odumosu has over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organizations.
    Mr Osagie Imasogie Non-Executive ChairmanNon-Executive Director Dec 2019
    Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President.
    Mr Greg Blake Executive Director Feb 2023
    Mr Blake has led the strategic development and commercialization of several products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch pathway and commercialization planning for both domestic and international markets.
    Dr Donna Gentile O'Donnell Non-Executive Director Jun 2023
    Dr O'Donnell served as Special Assistant to the President, Dr. Stephen K Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organizations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Malik Majeed 1,134,644 10.00%
    Quincy Street Capital Llc 456,622 4.02%
    Sharri J Rochlin <Rochlin Family Resource A/C> 393,168 3.46%
    Mr Zoltan Kerekes 393,168 3.46%
    Osagie Imasogie 393,168 3.47%
    Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 383,725 3.38%
    Ms Lisa Gray 381,988 3.37%
    Mera I Llc\C 332,479 2.93%
    Mr Torsten M Geers <The Torsten M Geers Living A/C> 307,454 2.71%
    Mr Steve Shapiro 302,571 2.67%
    Mara Gordon 252,242 2.22%
    Ubs Nominees Pty Ltd 160,689 1.42%
    Mr Saul Shorr and Mrs Margaret Shorr 151,285 1.33%
    Dr Chanda Latrice Macias 146,479 1.29%
    Mera Ii Llc\C 133,372 1.18%
    Citicorp Nominees Pty Limited 132,506 1.17%
    Oludare Odumosu 131,766 1.16%
    Muller Ct Pty Ltd <Muller Super Fund A/C> 118,107 1.04%
    Mr Daniel Hexter and Mrs Shannon Hexter 103,389 0.91%
    Geers Egag Llc 85,715 0.76%